Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit

American Journal of Respiratory and Critical Care Medicine

Volumn 166, Issue 6, 2002, Pages 839-842

  Saydain, Ghulam ^a   Islam, Ashiq ^a   Afessa, Bekele ^a   Ryu, Jay H ^a   Scott, John P ^a   Peters, Steve G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute Physiology and Chronic Health Evaluation; Mortality; Multiple organ failure; Pulmonary fibrosis; Sepsis

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE; LONG TERM CARE; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE ORGAN FAILURE; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; CHI-SQUARE DISTRIBUTION; DATA INTERPRETATION, STATISTICAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOME CARE SERVICES; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OXYGEN INHALATION THERAPY; PROGNOSIS; PULMONARY FIBROSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY FUNCTION TESTS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SEPSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037106503     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2104038     Document Type: Article

References (19)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
2. Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998;73:1085-1101.
3. Coultas DB, Zumwalt RE, Black WC. Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-972.
4. Panos RJ, Mortenson RL. Niccoli SA, King TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404.
5. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar FID, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157: 199-203.
6. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-296.
7. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996;51:711-716.
8. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996;153:1548-1552.
9. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619-1636.
10. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/ SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg 1985;202:685-693.
12. Johanson WG, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with gram-negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 1972;77:701-706.
13. Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alevolitis. Thorax 1983;38:349-355.
14. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:450-454.
15. Stack BH, Choo-Kang YF, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972;27:535-542.
16. Turner-Warwick M. Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980;35: 171-180.
17. Kondoh Y, Taniguchi H, Kawabata Y. Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-1812.
18. Matot I, Sprung CL. Definition of sepsis. Intensive Care Med 2001;27: S3-S9.
19. Nava S, Bubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 1999;54:390-395.